Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business c...
Ultimovacs ASA: Approval and publication of prospectus
Ultimovacs ASA: Cancellation of subsequent repair offering
Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update
Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation
Ultimovacs ASA: Notification of major holdings
Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025
Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting
Ultimovacs ASA: Regarding the extraordinary general meeting on 9 January 2025
Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 - CORRECTION
Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024
ULTI – EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY
Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA
Ultimovacs ASA – Mandatory notification of trade
ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update
Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in No...
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation
Ultimovacs Announces Notice of Resignation from Deputy Board Member
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head...
Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024
Ultimovacs ASA announces revised terms of the employee share option program
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer ...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
Ultimovacs – Invitation to Business Update on April 17, 2024
Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
Ultimovacs ASA: Mandatory notification of trade by primary insider
Ultimovacs ASA: Annual Report 2023
Ultimovacs ASA: Mandatory notification of trades by primary insider
Ultimovacs ASA: Mandatory notification of trade by primary insiders
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unrese...
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
Ultimovacs has been granted Orphan Drug Designation from the European Medicines Agency for its universal cancer vaccine, UV1, as a treatment...
Ultimovacs har erhållit särläkemedelsstatus från europeiska läkemedelsmyndigheten för bolagets universella cancervaccin, UV1, för behandling...
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March ...
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint
Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
Ultimovacs har meddelat positiva överlevnadsdata från fas II-studien NIPU som utvärderar det universella cancervaccinet UV1 vid malignt meso...
Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in malignant mesothe...
Ultimovacs ASA: New share capital registered
Ultimovacs ASA: Share capital increase related to exercise of options
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma
Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024
Ultimovacs Announces Webcast to Elaborate on the Results from Randomized UV1 Phase II NIPU Trial in Malignant Mesothelioma
Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Surv...
Ultimovacs har rapporterat positiva fas II-data gällande total överlevnad i mesoteliom med sin cancervaccinkandidat UV1.
Ultimovacs has reported positive phase II overall survival data with its cancer vaccine candidate UV1 in mesothelioma.
Vad? BioStock Life Science Summit När? 25-26 oktober Var? Hörsalen, Medicon Village, Scheeletorget 1, Lund Varför? Efter presentationen ...
Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients...
Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients ...
Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma
Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in Malignant Mesothelioma will be Presented at the ESMO Congres...
Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides General Business Update
Ultimovacs ASA: Invitation to second quarter 2023 results webcast presentation
Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients
Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results
Ultimovacs’ Chief Scientific Officer Gustav Gaudernack Receives Norwegian Tech Award’s Honorary Prize as an Outstanding Pioneer Against Canc...
Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with...
Ultimovacs har meddelat topline-data från fas II-studien NIPU som utvärderar det universella cancervaccinet UV1 i mesoteliom.
Ultimovacs has announced topline data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in mesothelioma.
Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma
Mesothelioma is a rare but aggressive form of cancer with limited treatment options.
Mesoteliom är en sällsynt men aggressiv form av cancer med begränsade behandlingsalternativ.
Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update
Ultimovacs ASA: Invitation to first quarter 2023 results webcast presentation
Fas II-studien INITIUM med Ultimovacs universella cancervaccin UV1 i malignt melanom skulle ha avlästs under första halvåret 2023.
The phase II INITIUM trial with Ultimovacs’ universal cancer vaccine UV1 in malignant melanoma was due for a data readout in the first half ...
Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma
Ultimovacs ASA - Share Option Program
Ultimovacs ASA – Annual General Meeting held on 20 April 2023
Ultimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
Ultimovacs ASA: Annual Report 2022
Ultimovacs to Present at Cowen Healthcare Conference
Cancervacciners populäritet växer snabbt inom den internationella biotekniksektorn, särskilt sedan välkända namn såsom Moderna och BioNTech ...
Cancer vaccines are quickly gaining popularity in the international biotech community, especially since household names like Moderna and Bio...
